SCHEMBL5029495

SCHEMBL5029495

CC(C)(C)NC1CCC(NC(=O)CNc2ncnc3ccc(-c4ccccc4C#N)cc23)CC1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 14/20 0.60
CYP3A4 P08684 14/20 0.60
CLK4 Q9HAZ1 10/20 0.60
CYP2C19 P33261 8/20 0.60
USP2 O75604 7/20 0.60
CYP2D6 P10635 6/20 0.60
LMNA P02545 6/20 0.60
ALDH1A1 P00352 10/20 0.59
HSD17B10 Q99714 10/20 0.59
ALOX15 P16050 2/20 0.59
CYP2C9 P11712 6/20 0.54
TSHR P16473 5/20 0.54
MAPK1 P28482 3/20 0.54
MEN1 O00255 3/20 0.54
KMT2A Q03164 3/20 0.54
BLM P54132 1/20 0.54
KDM4E B2RXH2 2/20 0.53
CCRL2 O00421 5/20 0.52
CCR2 P41597 1/20 0.52
KCNH2 Q12809 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5031899 0.87 CCRL2 (0.50) CYP1A2CYP3A4CLK4CYP2C19USP2
SCHEMBL5029207 0.87 CYP1A2 (0.60) CYP1A2CYP3A4CLK4CYP2C19USP2
SCHEMBL5027110 0.86 CCRL2 (0.51) CCRL2CCR2KCNH2IRAK4
SCHEMBL5027107 0.86 CCRL2 (0.51) CYP1A2CYP3A4CLK4CYP2C19USP2
SCHEMBL5027288 0.86 CYP1A2 (0.61) CYP1A2CYP3A4CLK4CYP2C19USP2
SCHEMBL5031903 0.86 IRAK4 (0.55) CYP1A2CYP3A4CLK4CYP2C19USP2
SCHEMBL5029621 0.83 CCRL2 (0.52) CCRL2CCR2KCNH2
SCHEMBL5027259 0.82 CCRL2 (0.53) CCRL2
SCHEMBL5033636 0.82 CCRL2 (0.55) CCRL2
SCHEMBL5029067 0.81 CCRL2 (0.51) CLK4CCRL2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7378409-B2 Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity BRISTOL-MYERS SQUIBB COMPANY (US) 2008-05-27 US disclosed
US-20050054626-A1 Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity BRISTOL-MYERS SQUIBB COMPANY 2005-03-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050054626-A1 Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity CCL11, CCR1, CCR2 CYP1A2 2798/4885CYP3A4 3690/4885CLK4 4765/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.